These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 8043686)

  • 1. Peritoneal dialysate magnesium--how low is safe?
    Weinreich T; Huynh U; Zitta S; Binder D; Gantenbein H; Binswanger U
    Perit Dial Int; 1994; 14(2):195-6. PubMed ID: 8043686
    [No Abstract]   [Full Text] [Related]  

  • 2. A higher magnesium dialysate concentration treats hypomagnesemia.
    Eisenman K; Holley JL
    Perit Dial Int; 2005; 25(6):604-5. PubMed ID: 16411530
    [No Abstract]   [Full Text] [Related]  

  • 3. Prevalence and factors associated with hypomagnesemia in Southern Chinese continuous ambulatory peritoneal dialysis patients.
    Ye H; Zhang X; Guo Q; Huang N; Mao H; Yu X; Yang X
    Perit Dial Int; 2013; 33(4):450-4. PubMed ID: 23843592
    [No Abstract]   [Full Text] [Related]  

  • 4. Hypomagnesemia in continuous ambulatory peritoneal dialysis patients dialyzed with a low-magnesium peritoneal dialysis solution.
    Ejaz AA; McShane AP; Gandhi VC; Leehey DJ; Ing TS
    Perit Dial Int; 1995; 15(1):61-4. PubMed ID: 7734563
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acute effects of different concentrations of dialysate magnesium during high-efficiency dialysis.
    Kelber J; Slatopolsky E; Delmez JA
    Am J Kidney Dis; 1994 Sep; 24(3):453-60. PubMed ID: 8079970
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized controlled trial to determine whether treatment with at neutral pH, low glucose degradation product dialysate (balance) prolongs residual renal function in peritoneal dialysis patients.
    Woodrow G
    Perit Dial Int; 2006; 26(1):113-4. PubMed ID: 16541510
    [No Abstract]   [Full Text] [Related]  

  • 7. A randomized controlled trial to determine whether treatment with at neutral pH, low glucose degradation product dialysate (balance) prolongs residual renal function in peritoneal dialysis patients.
    Brown F; Johnson DW
    Perit Dial Int; 2006; 26(1):112-3; author reply 114. PubMed ID: 16538887
    [No Abstract]   [Full Text] [Related]  

  • 8. [Influencing factors in the control of phosphorus in peritoneal dialysis. Therapeutic options].
    Gallar P; Ortega O; Gutiérrez M; Muñoz M; Hilara L; Oliet A; Rodríguez I; Giménez E; Vigil A
    Nefrologia; 2000; 20(4):355-61. PubMed ID: 11039261
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Composition of amino acid in blood and dialysate by patients with in chronic renal insufficiency by peritoneal dialysis].
    Pichugina IS; Gapparov MM; Chukarina EV; Vetchinnikova ON; Vatazin AV
    Vopr Pitan; 2008; 77(3):45-8. PubMed ID: 18669331
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reliable determination of furosine in human serum and dialysate proteins by high-performance liquid chromatography.
    Wu YC; Monnier V; Friedlander M
    J Chromatogr B Biomed Appl; 1995 May; 667(2):328-32. PubMed ID: 7663707
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Calcium and magnesium mass transfer in peritoneal dialysis patients using 1.25 mmol/L calcium, 0.25 mmol/L magnesium dialysis fluid.
    Hutchison AJ; Merchant M; Boulton HF; Hinchcliffe R; Gokal R
    Perit Dial Int; 1993; 13(3):219-23. PubMed ID: 8369353
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Procollagen type-I in the serum and dialysate of continuous ambulatory peritoneal dialysis patients.
    Digenis GE; Dombros NV; Christophoraki M; Grapsa I; Savidis N; Datseris J; Samuilidou E; Zerefos N; Tourkantonis A
    Perit Dial Int; 1993; 13 Suppl 2():S480-3. PubMed ID: 8399646
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Newer peritoneal dialysis solutions.
    Gokal R
    Adv Ren Replace Ther; 2000 Oct; 7(4):302-9. PubMed ID: 11073562
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intradialytic changes of serum magnesium and their relation to hypotensive episodes in hemodialysis patients on different dialysates.
    Elsharkawy MM; Youssef AM; Zayoon MY
    Hemodial Int; 2006 Oct; 10 Suppl 2():S16-23. PubMed ID: 17022745
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Elimination of NTproBNP in peritoneal dialysis patients. Does peritoneal membrane type make a difference in plasma level and elimination of NTproBNP?
    Koz S; Sahin I; Temel I; Koz ST; Terzi Z
    Clin Nephrol; 2016 May; 85(5):266-72. PubMed ID: 27007867
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low calcium (2.5 mEq/l) and high calcium (3.5 mEq/l) dialysate in peritoneal dialysis patients.
    Wadhwa NK; Howell N; Suh H; Cabralda T
    Adv Perit Dial; 1992; 8():385-8. PubMed ID: 1361829
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Levels of transforming growth factor β1 during first six months of peritoneal dialysis.
    Stojimirović B; Jovanović N; Trbojević-Stanković J; Nešić DM; Brašanac T; Žunić-Božinovski S
    Ren Fail; 2015 May; 37(4):640-5. PubMed ID: 25682975
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Leptin in peritoneal dialysate from continuous ambulatory peritoneal dialysis patients.
    Tsujimoto Y; Shoji T; Tabata T; Morita A; Emoto M; Nishizawa Y; Morii H
    Am J Kidney Dis; 1999 Nov; 34(5):832-8. PubMed ID: 10561138
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationship between the serum parathyroid hormone and magnesium levels in continuous ambulatory peritoneal dialysis (CAPD) patients using low-magnesium peritoneal dialysate.
    Cho MS; Lee KS; Lee YK; Ma SK; Ko JH; Kim SW; Kim NH; Choi KC
    Korean J Intern Med; 2002 Jun; 17(2):114-21. PubMed ID: 12164088
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association Between Peritoneal Glucose Exposure and Peritonitis in Peritoneal Dialysis Patients: The balANZ Trial.
    Nataatmadja M; Cho Y; Pascoe EM; Darssan D; Hawley CM; Johnson DW;
    Perit Dial Int; 2017; 37(4):407-413. PubMed ID: 28408714
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.